Bullous Pemphigoid: Clinical Trials

12 trials for Bullous Pemphigoid, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 3 terminated, 1 unknown. 12 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Completed 8, Terminated 3, Unknown 1
Phase 32Completed 2
Phase 11Completed 1

Follow Bullous Pemphigoid: new trials by email Literature Review of Bullous Pemphigoid trials Research Report on Bullous Pemphigoid

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
efgartigimod PH20 SC, placebo, Prednisone - Bullous Pemphigoid
Phase 2 / Phase 3Completedargenx982022-06-092025-10-23
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
dupilumab, Matching Placebo, Oral corticosteroids (OCS) - Bullous Pemphigoid
Phase 2 / Phase 3CompletedRegeneron Pharmaceuticals1062020-10-282026-06-18
Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody
Avdoralimab (IPH5401), Control - Bullous Pemphigoid
Phase 2CompletedCentre Hospitalier Universitaire de Nice152020-10-102026-03-24
Efficacy and Safety of Ustekinumab in Bullous Pemphigoid
Ustekinumab - Bullous Pemphigoid
Phase 2CompletedCHU de Reims182020-03-112023-08-08
A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid
AC-203 1% Topical Ointment, Clobetasol 0.05% Topical Ointment - Bullous Pemphigoid
Phase 2TerminatedTWi Biotechnology, Inc.102017-09-052019-09-19
Ixekizumab in the Treatment of Bullous Pemphigoid
Ixekizumab - Bullous Pemphigoid, Pemphigoid
Phase 2CompletedMayo Clinic42017-08-152020-05-21
Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment
QGE031, Placebo - Bullous Pemphigoid
Phase 2TerminatedNovartis Pharmaceuticals202013-01-012016-04-28
Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid
DF2156A - Bullous Pemphigoid
Phase 2TerminatedDompé Farmaceutici S.p.A42012-02-202023-12-22
Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.
NPB-01, Placebo - Bullous Pemphigoid
Phase 2CompletedNihon Pharmaceutical Co., Ltd202008-11-012010-10-25
Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid
leflunomide - Bullous Pemphigoid
Phase 2UnknownUniversity Hospital, Limoges542007-09-012008-12-04
Rituximab in the Treatment of Patients With Bullous Pemphigoid
Rituximab - Bullous Pemphigoid
Phase 1 / Phase 2CompletedDuke University82005-03-012013-04-11
Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid
Azathioprine or Mycophenolate mofetil - Bullous Pemphigoid
Phase 2CompletedUniversity Hospital Muenster701997-10-012007-02-05

Narrower conditions

Pemphigoid, Bullous (12)

Broader conditions

Autoimmune Diseases (12)  ·  Immune System Diseases (12)  ·  Skin Diseases (12)  ·  Skin Diseases, Vesiculobullous (12)  ·  Skin and Connective Tissue Diseases (12)

Interventions

2'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide (1)  ·  Adrenal Cortex Hormones (1)  ·  Azathioprine (1)  ·  Clobetasol (1)  ·  Leflunomide (1)  ·  Mycophenolic Acid (1)  ·  Ointments (1)  ·  Prednisone (1)  ·  Rituximab (1)  ·  Ustekinumab (1)  ·  avdoralimab (1)  ·  diacerein (1)  ·  dupilumab (1)  ·  ixekizumab (1)  ·  ligelizumab (1)

Sponsors

CHU de Reims (1)  ·  Centre Hospitalier Universitaire de Nice (1)  ·  DompĂ© Farmaceutici S.p.A (1)  ·  Duke University (1)  ·  Mayo Clinic (1)  ·  Nihon Pharmaceutical Co., Ltd (1)  ·  Novartis Pharmaceuticals (1)  ·  Regeneron Pharmaceuticals (1)  ·  TWi Biotechnology, Inc. (1)  ·  University Hospital Muenster (1)  ·  University Hospital, Limoges (1)  ·  argenx (1)

Countries

France (6)  ·  Germany (5)  ·  United States (5)  ·  Japan (4)  ·  Taiwan (3)  ·  Australia (2)  ·  Israel (2)  ·  Italy (2)  ·  Poland (2)  ·  Spain (2)  ·  Austria (1)  ·  Bulgaria (1)  ·  China (1)  ·  Croatia (1)  ·  Czechia (1)

Top investigators

Aaron Mangold, MD (1)  ·  Andrea Kneisel, MD (1)  ·  Biagio Didona, MD (1)  ·  Detlef Zillikens, MD (1)  ·  Johannes Kern, MD (1)  ·  Passeron Thierry, PhD (1)  ·  Pier Adelchi Ruffini, MD (1)  ·  Russell Hall, III, MD (1)  ·  Stefan Beissert, MD (1)

Results publications

PMID 18087004, PMID 38443648, PMID 38508975, PMID 39310808

NIH funding

2019 (1)